MARKET

XBIT

XBIT

Xbiotech
NASDAQ
6.22
-0.44
-6.61%
After Hours: 6.35 +0.13 +2.09% 19:28 07/12 EDT
OPEN
6.66
PREV CLOSE
6.66
HIGH
6.77
LOW
6.06
VOLUME
60.29K
TURNOVER
0
52 WEEK HIGH
9.96
52 WEEK LOW
3.510
MARKET CAP
189.45M
P/E (TTM)
-6.1590
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at XBIT last week (0701-0705)?
Weekly Report · 6d ago
XBiotech Inc. (NASDAQ:XBIT) surges 26%; individual investors who own 51% shares profited along with insiders
Insiders own 35% of XBiotech Inc. (NASDAQ:XBIT) 47% of the business is held by the top 25 shareholders of the company. The majority of shares are held by individual investors. The company has a large number of shareholders, but there is no institutional ownership. X biotech is owned by the general public, but the company is not widely held by institutions. XBi biotech saw a 26% increase in its share price last week. We look at the shareholders of X Biotech to see how the company differs from other companies.
Simply Wall St · 07/05 10:52
Weekly Report: what happened at XBIT last week (0624-0628)?
Weekly Report · 07/01 09:13
Weekly Report: what happened at XBIT last week (0617-0621)?
Weekly Report · 06/24 09:14
What's Going On With Small-Cap Cancer Focused XBiotech On Tuesday?
XBiotech Inc announced data from its Phase 1/Phase 2, 1-BETTER Study for advanced pancreatic cancer. The study examined the Natrunix anti-cancer antibody in combination with an established chemotherapy regimen. The company believes the drug could potentially improve tolerability of the chemotherapy.
Benzinga · 06/18 17:08
XBiotech Studies Find Potential Treatment for Advanced Pancreatic Cancer
Dow Jones · 06/18 16:21
XBIOTECH RESULTS FROM RANDOMIZED DOUBLE-BLINDED PHASE 1/2 STUDY SUGGEST POTENTIAL BREAKTHROUGH TREATMENT FOR ADVANCED PANCREATIC CANCER
Reuters · 06/18 15:35
Weekly Report: what happened at XBIT last week (0610-0614)?
Weekly Report · 06/17 09:13
More
About XBIT
XBiotech Inc. is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies for treating a variety of diseases, such as inflammatory conditions like rheumatology, infectious disease, cardiovascular disease and cancer. The Company's True Human monoclonal antibodies are derived from human donors that mount a natural human immune response. The Company is focused on therapies that block a potent substance, known as interleukin-1 alpha (IL-1a), that mediates a number of pathophysiological processes including tissue breakdown (i.e. synovium, cartilage, bone), paraneoplastic angiogenesis and tumor stroma remodeling, formation of blood clots, malaise, muscle wasting and general inflammation. It has various candidate products including Natrunix. It has a clinical-stage therapeutic for methicillin resistant Staphylococcus aureus (MRSA), and several pre-clinical-stage therapeutics, including an oral delivery antibody therapeutic for colon infection by C. difficile.

Webull offers XBiotech Inc stock information, including NASDAQ: XBIT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XBIT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading XBIT stock methods without spending real money on the virtual paper trading platform.